Supernus Pharmaceuticals Management
Management criteria checks 2/4
Supernus Pharmaceuticals' CEO is Jack Khattar, appointed in Jan 2005, has a tenure of 19.33 years. total yearly compensation is $13.28M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 3.52% of the company’s shares, worth $59.74M. The average tenure of the management team and the board of directors is 9.1 years and 13.3 years respectively.
Key information
Jack Khattar
Chief executive officer
US$13.3m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 19.3yrs |
| CEO ownership | 3.5% |
| Management average tenure | 9.1yrs |
| Board average tenure | 13.3yrs |
Recent management updates
Recent updates
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24
Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29Supernus: New Beginnings
Mar 28Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts
Dec 02Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?
Nov 30Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?
Oct 19Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?
Aug 31Supernus: Well Prepared For Upcoming Challenges
Aug 26Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly
Jul 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$13m | US$963k | US$1m |
| Sep 30 2023 | n/a | n/a | US$26m |
| Jun 30 2023 | n/a | n/a | US$43m |
| Mar 31 2023 | n/a | n/a | US$52m |
| Dec 31 2022 | US$10m | US$914k | US$61m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$57m |
| Mar 31 2022 | n/a | n/a | US$73m |
| Dec 31 2021 | US$8m | US$870k | US$53m |
| Sep 30 2021 | n/a | n/a | US$82m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$111m |
| Dec 31 2020 | US$7m | US$836k | US$127m |
| Sep 30 2020 | n/a | n/a | US$129m |
| Jun 30 2020 | n/a | n/a | US$118m |
| Mar 31 2020 | n/a | n/a | US$116m |
| Dec 31 2019 | US$8m | US$812k | US$113m |
| Sep 30 2019 | n/a | n/a | US$106m |
| Jun 30 2019 | n/a | n/a | US$105m |
| Mar 31 2019 | n/a | n/a | US$103m |
| Dec 31 2018 | US$7m | US$724k | US$111m |
| Sep 30 2018 | n/a | n/a | US$99m |
| Jun 30 2018 | n/a | n/a | US$87m |
| Mar 31 2018 | n/a | n/a | US$73m |
| Dec 31 2017 | US$6m | US$614k | US$57m |
Compensation vs Market: Jack's total compensation ($USD13.28M) is above average for companies of similar size in the US market ($USD5.67M).
Compensation vs Earnings: Jack's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Jack Khattar (62 yo)
19.3yrs
Tenure
US$13,278,093
Compensation
Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 19.3yrs | US$13.28m | 3.52% $ 59.7m | |
| Senior VP & CFO | 2.8yrs | US$2.38m | 0.013% $ 221.7k | |
| Chief Scientific Officer & Senior VP of Intellectual Property | 12.2yrs | US$1.47m | 0.016% $ 264.2k | |
| Senior Vice President of Quality | 4.3yrs | US$1.79m | 0.014% $ 239.8k | |
| Senior VP of Research & Development and Chief Medical Officer | 4.3yrs | US$1.59m | 0.0084% $ 143.0k | |
| Compliance Officer | 12.3yrs | no data | no data | |
| Senior Vice President of Marketing & Market Access | 9.3yrs | no data | no data | |
| Senior Vice President of Sales | 9.3yrs | no data | no data | |
| Senior Vice President of Corporate Development | 8.8yrs | no data | no data | |
| Senior Vice President of Supply Chain | 3yrs | no data | no data |
9.1yrs
Average Tenure
62yo
Average Age
Experienced Management: SUPN's management team is seasoned and experienced (9.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 19.3yrs | US$13.28m | 3.52% $ 59.7m | |
| Independent Chairman of the Board | 19.3yrs | US$407.02k | 0.22% $ 3.7m | |
| Independent Director | 13.3yrs | US$392.52k | 0.16% $ 2.7m | |
| Independent Director | 9.2yrs | US$378.52k | 0.031% $ 530.3k | |
| Independent Director | 5.9yrs | US$376.02k | 0.031% $ 530.3k | |
| Independent Director | 14.3yrs | US$385.02k | 0.068% $ 1.1m | |
| Independent Director | less than a year | US$514.39k | no data |
13.3yrs
Average Tenure
63yo
Average Age
Experienced Board: SUPN's board of directors are seasoned and experienced ( 13.3 years average tenure).